240 related articles for article (PubMed ID: 12538702)
21. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.
Chen H; Xiang ZQ; Li Y; Kurupati RK; Jia B; Bian A; Zhou DM; Hutnick N; Yuan S; Gray C; Serwanga J; Auma B; Kaleebu P; Zhou X; Betts MR; Ertl HC
J Virol; 2010 Oct; 84(20):10522-32. PubMed ID: 20686035
[TBL] [Abstract][Full Text] [Related]
22. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.
Xiang Z; Gao G; Reyes-Sandoval A; Cohen CJ; Li Y; Bergelson JM; Wilson JM; Ertl HC
J Virol; 2002 Mar; 76(6):2667-75. PubMed ID: 11861833
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
24. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.
Casimiro DR; Chen L; Fu TM; Evans RK; Caulfield MJ; Davies ME; Tang A; Chen M; Huang L; Harris V; Freed DC; Wilson KA; Dubey S; Zhu DM; Nawrocki D; Mach H; Troutman R; Isopi L; Williams D; Hurni W; Xu Z; Smith JG; Wang S; Liu X; Guan L; Long R; Trigona W; Heidecker GJ; Perry HC; Persaud N; Toner TJ; Su Q; Liang X; Youil R; Chastain M; Bett AJ; Volkin DB; Emini EA; Shiver JW
J Virol; 2003 Jun; 77(11):6305-13. PubMed ID: 12743287
[TBL] [Abstract][Full Text] [Related]
25. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
26. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
27. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
28. Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors.
Bassett JD; Swift SL; Bramson JL
Expert Rev Vaccines; 2011 Sep; 10(9):1307-19. PubMed ID: 21919620
[TBL] [Abstract][Full Text] [Related]
29. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
McGettigan JP; Sarma S; Orenstein JM; Pomerantz RJ; Schnell MJ
J Virol; 2001 Sep; 75(18):8724-32. PubMed ID: 11507217
[TBL] [Abstract][Full Text] [Related]
30. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
[TBL] [Abstract][Full Text] [Related]
31. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines.
Singh RA; Barry MA
J Immunol; 2004 Oct; 173(7):4387-93. PubMed ID: 15383568
[TBL] [Abstract][Full Text] [Related]
32. A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development.
Luo S; Zhang P; Ma X; Wang Q; Lu J; Liu B; Zhao W; Allain JP; Li C; Li T
Virus Res; 2019 Jul; 268():1-10. PubMed ID: 31108113
[TBL] [Abstract][Full Text] [Related]
33. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
34. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
35. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.
Breton M; Zhao C; Ouellette M; Tremblay MJ; Papadopoulou B
J Gen Virol; 2007 Jan; 88(Pt 1):217-225. PubMed ID: 17170454
[TBL] [Abstract][Full Text] [Related]
36. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
[TBL] [Abstract][Full Text] [Related]
37. Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV.
Rojas JM; Moreno H; García A; Ramírez JC; Sevilla N; Martín V
Vaccine; 2014 Jan; 32(3):393-400. PubMed ID: 24269622
[TBL] [Abstract][Full Text] [Related]
38. Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus.
Phillpotts RJ; O'brien L; Appleton RE; Carr S; Bennett A
Vaccine; 2005 Feb; 23(13):1615-23. PubMed ID: 15694514
[TBL] [Abstract][Full Text] [Related]
39. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.
Lin SW; Cun AS; Harris-McCoy K; Ertl HC
Vaccine; 2007 Mar; 25(12):2187-93. PubMed ID: 17229501
[TBL] [Abstract][Full Text] [Related]
40. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys.
Prevec L; Christie BS; Laurie KE; Bailey MM; Graham FL; Rosenthal KL
J Acquir Immune Defic Syndr (1988); 1991; 4(6):568-76. PubMed ID: 1902514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
